À propos 7 years of successful life-cycle management of 5 brands (3 Rx and 2 OTC) of Berlin-Chemie Menarini group which appeared to be in the TOP-3 of the corresponding segments (Pain and inflammation management, Headache, Fever), in particular:
- NSAIDs portfolio under my management reached the largest share amount all product portfolios of Berlin-Chemie AG in Ukraine as for 2013;
- Successful launch of two new products (Rx: Dexalgin; OTC: Imet) in 2006;
- Nimesil became the Market leader in M01B2 segment as of 2012 and was awarded as “Best Rx-product 2012” at the Panacea Award;
- Rewarding relationship building with more than 63 national KOLs in 13 therapeutic areas.